Zensar Technologies has announced its Board of Directors has granted in-principle approval for the merger of its US-based step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into its material wholly owned subsidiary, Zensar Technologies Inc., USA. This strategic move aims to achieve greater business synergies, higher operational efficiencies, and unified control of operations. The merging entities will cease to exist post-merger.
Strategic Merger Approval
The Board of Directors of Zensar Technologies Limited convened on July 29, 2026, and has given its in-principle approval for a significant internal restructuring. The company plans to merge two of its US-based step-down subsidiaries: Bridgeview Life Sciences LLC and M3BI LLC, into its material wholly owned subsidiary, Zensar Technologies Inc., USA. This merger is intended to be executed either directly or indirectly through the formation of a new entity if necessary.
Rationale and Expected Outcomes
The primary objective behind this proposed merger is to foster greater business synergies and achieve enhanced operational efficiencies. Zensar Technologies anticipates that this consolidation will also lead to more effective management and a unified control over its operations. Following the successful completion of the merger, Bridgeview Life Sciences LLC and M3BI LLC will no longer exist as separate step-down subsidiaries of Zensar Technologies Limited.
Key Entities and Financials
As of the year ended March 31, 2026, the entities involved have the following financial standing (standalone basis, in USD Million):
- Bridgeview Life Sciences LLC: Net worth of 0.4, Turnover of 4.74.
- M3BI LLC: Net worth of 9.32, Turnover of 46.8.
- Zensar Technologies Inc.: Net worth of 74.66, Turnover of 326.96.
Business Areas and Transaction Details
All involved entities are engaged in providing digital solutions and technology services to global organizations. The transaction itself is considered internal and does not fall under related party transaction provisions as per Regulation 23(5)(b) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Consequently, there will be no change in the shareholding pattern of Zensar Technologies Limited.
Board Meeting Details
The Board meeting where this approval was granted commenced at 05:00 PM (IST) and concluded at 08:05 PM (IST) on July 29, 2026.
Source: BSE
